Breaking News
A vaccine candidate called GBP511 that builds upon a self-assembling nanoparticle technology has begun human clinical testing in Australia.
FDA has granted fast track designation to gamgertamig (OM336) for the treatment of immune thrombocytopenia and cold and warm autoimmune hemolytic anemia.
A clinical tria that evaluated an alpha-lactalbumin (aLA) vaccine demonstrated an immune response in 74 percent of patients who presently have or are at high risk for triple-negative breast cancer.
BioTrending
- By Amy Scanlin, MS
This revolutionary technology shows promise for addressing a myriad of challenges in medicine, but ethical dilemmas remain.
- By Diane L.M. Cook
Known as liquid gold, human plasma is proving to be a valuable ally in the fight against cancer.
- By Jim Trageser
While still in their early stages of research, FDA has approved more than a dozen complement inhibitors to treat various conditions, and there is hope that more will be on the horizon to treat others.
- By Trudie Mitschang
Virtual hospitals bring hospital-level care directly to patients' homes, representing a transformative step in healthcare delivery.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
